While therapies are limited in preventing BPD, our current finding lays the framework for the use of targeted approaches, such as reducing Keap1 expression and/or inhibiting its interaction with Nrf2, as pharmacological ways to prevent BPD pathogenesis associated with prematurity in the clinical setting. Here, KEAP1 is linked to bronchopulmonary dysplasia.